Uncovering the Anticancer Potential of Murine Cytomegalovirus against Human Colon Cancer Cells.
Anti-tumor potential
Cross-species
Decreased host defense
Human Colon cancer
IFN-B
Virotherapy
hCMV
mCMV
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
27 Mar 2020
27 Mar 2020
Historique:
received:
09
01
2020
accepted:
22
01
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) components are often found in tumors, but the precise relationship between HCMV and cancer remains a matter of debate. Pro-tumor functions of HCMV were described in several studies, but an association between HCMV seropositivity and reduced cancer risk was also evidenced, presumably relying on recognition and killing of cancer cells by HCMV-induced lymphocytes. This study aimed at deciphering whether CMV influences cancer development in an immune-independent manner. Using immunodeficient mice, we showed that systemic infection with murine CMV (MCMV) inhibited the growth of murine carcinomas. Surprisingly, MCMV, but not HCMV, also reduced human colon carcinoma development
Identifiants
pubmed: 32140563
doi: 10.1016/j.omto.2020.01.007
pii: S2372-7705(20)30017-6
pmc: PMC7052516
doi:
Types de publication
Journal Article
Langues
eng
Pagination
250-261Informations de copyright
© 2020 The Author(s).
Références
Infect Immun. 1972 Nov;6(5):793-7
pubmed: 4118017
EBioMedicine. 2018 Apr;30:167-183
pubmed: 29628341
Nature. 2009 Oct 8;461(7265):788-92
pubmed: 19776740
Mol Ther. 2016 Aug;24(8):1444-55
pubmed: 27434584
Leuk Lymphoma. 2015;56(11):3189-97
pubmed: 25818505
J Virol. 2016 Apr 14;90(9):4346-4356
pubmed: 26889030
PLoS One. 2013;8(3):e59591
pubmed: 23555719
J Biol Chem. 2006 Dec 8;281(49):37652-60
pubmed: 17035242
mBio. 2016 Nov 15;7(6):
pubmed: 27935834
J Gen Virol. 2011 Jul;92(Pt 7):1532-1538
pubmed: 21471311
PLoS Pathog. 2011 Oct;7(10):e1002295
pubmed: 21998590
J Gen Virol. 2016 Sep;97(9):2411-2420
pubmed: 27435237
Science. 1976 Jun 11;192(4244):1134-7
pubmed: 179143
Int J Oncol. 2007 Sep;31(3):613-20
pubmed: 17671689
J Interferon Cytokine Res. 2007 Aug;27(8):675-80
pubmed: 17784819
Science. 2013 May 24;340(6135):1237874
pubmed: 23704576
Nature. 2011 May 26;473(7348):523-7
pubmed: 21562493
Immunity. 2015 Oct 20;43(4):634-45
pubmed: 26488815
BMC Cancer. 2018 May 30;18(1):609
pubmed: 29848298
Nat Immunol. 2012 Sep;13(9):872-9
pubmed: 22885985
J Virol. 2016 Aug 12;90(17):7789-97
pubmed: 27334590
Neoplasia. 2009 Jan;11(1):1-9
pubmed: 19107226
Oncotarget. 2016 Nov 22;7(47):76735-76742
pubmed: 27732934
Intervirology. 1996;39(4):259-69
pubmed: 9078467
Leukemia. 2013 Jun;27(6):1328-38
pubmed: 23277330
Clin Exp Immunol. 2018 Sep;193(3):265-274
pubmed: 29737525
Viruses. 2018 Aug 03;10(8):
pubmed: 30081496
PLoS Pathog. 2016 Apr 08;12(4):e1005546
pubmed: 27058035
J Exp Med. 2005 May 16;201(10):1567-78
pubmed: 15897274
Immunotherapy. 2016 Feb;8(2):211-21
pubmed: 26786895
Mol Immunol. 2009 Oct;46(16):3462-5
pubmed: 19716178
Blood. 2011 Aug 4;118(5):1402-12
pubmed: 21540462
Sci Rep. 2016 Feb 15;6:21674
pubmed: 26876974
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3163-3168
pubmed: 28270598
Biol Blood Marrow Transplant. 2016 Feb;22(2):300-306
pubmed: 26371373
PLoS One. 2015 Oct 06;10(10):e0139603
pubmed: 26441059
Oncoimmunology. 2015 Feb 3;4(5):e1003011
pubmed: 26155394
Front Immunol. 2018 Mar 01;9:389
pubmed: 29545802
Int J Oncol. 2017 Nov;51(5):1415-1426
pubmed: 29048611
J Immunother. 2012 Jun;35(5):390-9
pubmed: 22576344
PLoS Pathog. 2014 Feb 20;10(2):e1003962
pubmed: 24586165
J Immunol. 2014 Oct 15;193(8):4254-60
pubmed: 25217157
J Neurooncol. 2015 Jul;123(3):465-71
pubmed: 25682092
Cancer Immunol Res. 2015 May;3(5):536-46
pubmed: 25633711
J Virol. 2006 Aug;80(15):7510-21
pubmed: 16840331
Oncoimmunology. 2015 Jun 5;5(1):e1056974
pubmed: 26942064
Transpl Int. 2011 May;24(5):e40-2
pubmed: 21463369
J Virol. 2003 Jul;77(13):7182-92
pubmed: 12805417
EMBO J. 2006 Jun 7;25(11):2634-42
pubmed: 16688216
Blood. 2013 Aug 15;122(7):1316-24
pubmed: 23744585
Cancer Res. 2015 Aug 1;75(15):3065-76
pubmed: 26239477
J Virol. 2006 May;80(10):4801-19
pubmed: 16641273
Oncotarget. 2016 Nov 8;7(45):74393-74409
pubmed: 27626310
J Interferon Cytokine Res. 2004 Apr;24(4):231-43
pubmed: 15144569
Mol Ther Oncolytics. 2016 Apr 27;3:16012
pubmed: 27626063
Front Immunol. 2018 Jan 16;8:1993
pubmed: 29387061
Hum Vaccin Immunother. 2017 Aug 3;13(8):1778-1785
pubmed: 28604162
Clin Microbiol Infect. 2014 Jul;20(7):664-71
pubmed: 24118412
Front Immunol. 2017 Feb 09;8:105
pubmed: 28232834
J Gen Virol. 1988 Feb;69 ( Pt 2):355-74
pubmed: 2828515
J Gen Virol. 2017 Jul;98(7):1795-1805
pubmed: 28745271
Cell Rep. 2016 Jan 12;14(2):282-97
pubmed: 26748708
Cancer Res. 2013 Jun 1;73(11):3441-50
pubmed: 23729642
Oncotarget. 2011 Dec;2(12):1329-38
pubmed: 22246171
Front Oncol. 2014 Nov 17;4:314
pubmed: 25452935
Biol Blood Marrow Transplant. 2014 Jan;20(1):46-52
pubmed: 24120526